A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)

Date Added
August 8th, 2023
PRO Number
Pro00130428
Researcher
Ashley Waring

List of Studies

Keywords
Cardiovascular, Cholesterol, Drug Studies
Summary

This study is enrolling participants with elevated lipoprotein (a) levels, a cholesterol like substance, to test an investigational study medication called olpasiran. Investigational means it has not yet been approved by the US Food and Drug Administration (FDA) for commercial use but has been approved for use in this study. Olpasiran is a subcutaneous injection given every 12 weeks. This study is randomized, which means participants are randomly assigned, like the flip of a coin, to either receive olpasiran or placebo. Placebo looks like the study medication but has no active ingredients. Neither the participants nor the study doctor or study team will know if you are getting study medication or placebo. Participation in this study will last up to 4 1/2 years and include about 14-24 study visits. Study procedures include physical exams, medical history and medication review, electrocardiograms (tracing of the electrical activity of your heart), blood work, questionnaires and medication administration.

Institution
MUSC
Recruitment Contact
Deborah Everidge
843-792-2944
adamsde@musc.edu

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia

Date Added
July 18th, 2023
PRO Number
Pro00127774
Researcher
Marc-Andre Cornier

List of Studies

Keywords
Cardiovascular, Cholesterol, Drug Studies, Men's Health, Women's Health
Summary

This clinical research study is enrolling adults who have high triglycerides (fats in the blood). The study drug, olezarsen, is an investigational drug designed to reduce triglyceride blood levels. If you meet the requirements to participate in this study, you will be randomly assigned to receive either olezarsen or placebo (an inactive substance that contains no drug). During the treatment period, participants will be asked to complete visits every 4 weeks to include a total of 21 visits over approximately 16 months. If eligible, study medication and study visits will be provided free of charge. Compensation is available.

Institution
MUSC
Recruitment Contact
Kelcey Ladner
843-792-6043
ladnerk@musc.edu

PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr adults (PREVENTABLE)

Date Added
March 6th, 2023
PRO Number
Pro00125689
Researcher
Leslie Lenert

List of Studies